Acrivon Therapeutics (NASDAQ:ACRV) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Acrivon Therapeutics (NASDAQ:ACRV) from a hold rating to a sell rating in a report released on Sunday.

Other research analysts also recently issued reports about the company. Piper Sandler boosted their target price on Acrivon Therapeutics from $6.00 to $8.00 and gave the stock an “overweight” rating in a research note on Friday, January 9th. HC Wainwright reissued a “buy” rating and issued a $19.00 price target on shares of Acrivon Therapeutics in a report on Tuesday, November 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Acrivon Therapeutics in a research note on Monday, December 29th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Acrivon Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

Acrivon Therapeutics Stock Performance

Shares of Acrivon Therapeutics stock opened at $1.51 on Friday. The company has a market capitalization of $47.66 million, a PE ratio of -0.71 and a beta of 1.79. The company has a 50-day simple moving average of $1.94 and a two-hundred day simple moving average of $1.92. Acrivon Therapeutics has a one year low of $1.05 and a one year high of $5.75.

Insider Buying and Selling

In other news, CEO Peter Blume-Jensen purchased 49,000 shares of the stock in a transaction on Wednesday, January 14th. The stock was bought at an average price of $1.68 per share, with a total value of $82,320.00. Following the transaction, the chief executive officer owned 2,095,771 shares in the company, valued at $3,520,895.28. The trade was a 2.39% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders bought 67,832 shares of company stock worth $114,534. Insiders own 8.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Acrivon Therapeutics during the fourth quarter worth about $44,000. Quadrature Capital Ltd purchased a new position in Acrivon Therapeutics during the 4th quarter worth approximately $50,000. Bridgeway Capital Management LLC lifted its stake in Acrivon Therapeutics by 87.3% during the 4th quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $103,000 after acquiring an additional 20,000 shares during the period. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Acrivon Therapeutics in the 4th quarter valued at $40,000. Finally, Marshall Wace LLP boosted its holdings in shares of Acrivon Therapeutics by 231.4% in the 4th quarter. Marshall Wace LLP now owns 496,081 shares of the company’s stock valued at $1,196,000 after acquiring an additional 346,366 shares during the last quarter. 71.62% of the stock is currently owned by hedge funds and other institutional investors.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.